Advertisement
Research Article

Neurobeachin, a Regulator of Synaptic Protein Targeting, Is Associated with Body Fat Mass and Feeding Behavior in Mice and Body-Mass Index in Humans

  • Pawel K. Olszewski,

    Affiliations: Functional Pharmacology Unit, Department of Neuroscience, Uppsala University, Uppsala, Sweden, Minnesota Obesity Center, University of Minnesota, St. Paul, Minnesota, United States of America

    Current address: Department of Biological Sciences, University of Waikato, Hamilton, New Zealand

    X
  • Jan Rozman,

    Affiliations: German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, Molecular Nutritional Medicine, Else Kröner-Fresenius Center and ZIEL Research Center for Nutrition and Food Sciences, Technische Universität München, Freising-Weihenstephan, Germany

    X
  • Josefin A. Jacobsson,

    Affiliation: Functional Pharmacology Unit, Department of Neuroscience, Uppsala University, Uppsala, Sweden

    X
  • Birgit Rathkolb,

    Affiliations: German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, Chair for Molecular Animal Breeding and Biotechnology, Gene Center, Ludwig-Maximilians-Universität München, München, Germany

    X
  • Siv Strömberg,

    Affiliation: Molecular Cell Biology Unit, Department of Neuroscience, Uppsala University, Uppsala, Sweden

    X
  • Wolfgang Hans,

    Affiliation: German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

    X
  • Anica Klockars,

    Affiliation: Functional Pharmacology Unit, Department of Neuroscience, Uppsala University, Uppsala, Sweden

    X
  • Johan Alsiö,

    Affiliation: Functional Pharmacology Unit, Department of Neuroscience, Uppsala University, Uppsala, Sweden

    X
  • Ulf Risérus,

    Affiliation: Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden

    X
  • Lore Becker,

    Affiliations: German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, Department of Neurology, Friedrich-Baur-Institut, Ludwig-Maximilians-Universität München, München, Germany

    X
  • Sabine M. Hölter,

    Affiliations: German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Developmental Genetics, Neuherberg, Germany

    X
  • Ralf Elvert,

    Affiliation: German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

    Current address: Sanofi-Aventis GmbH, Frankfurt am Main, Germany

    X
  • Nicole Ehrhardt,

    Affiliation: German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

    Current address: Department of Medical Genetics, Cedars-Sinai Medical Center, Los Angeles, California, United States of America

    X
  • Valérie Gailus-Durner,

    Affiliation: German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

    X
  • Helmut Fuchs,

    Affiliation: German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

    X
  • Robert Fredriksson,

    Affiliation: Functional Pharmacology Unit, Department of Neuroscience, Uppsala University, Uppsala, Sweden

    X
  • Eckhard Wolf,

    Affiliation: Chair for Molecular Animal Breeding and Biotechnology, Gene Center, Ludwig-Maximilians-Universität München, München, Germany

    X
  • Thomas Klopstock,

    Affiliation: Department of Neurology, Friedrich-Baur-Institut, Ludwig-Maximilians-Universität München, München, Germany

    X
  • Wolfgang Wurst,

    Affiliations: Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Developmental Genetics, Neuherberg, Germany, Max-Planck-Institute for Psychiatry, München, Germany, Technical University München-Weihenstephan, Lehrstuhl für Entwicklungsgenetik c/o Helmholtz Zentrum München, Neuherberg, Germany, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Munich, Germany

    X
  • Allen S. Levine,

    Affiliation: Minnesota Obesity Center, University of Minnesota, St. Paul, Minnesota, United States of America

    X
  • Claude Marcus,

    Affiliation: Department for Clinical Science, Intervention, and Technology, Karolinska Institutet, Division of Pediatrics, National Childhood Obesity Centre, Stockholm, Sweden

    X
  • Martin Hrabě de Angelis,

    Affiliations: German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, Lehrstuhl für Experimentelle Genetik, Technische Universität München, Freising-Weihenstephan, Germany

    X
  • Martin Klingenspor,

    Affiliation: Molecular Nutritional Medicine, Else Kröner-Fresenius Center and ZIEL Research Center for Nutrition and Food Sciences, Technische Universität München, Freising-Weihenstephan, Germany

    X
  • Helgi B. Schiöth ,

    Affiliation: Functional Pharmacology Unit, Department of Neuroscience, Uppsala University, Uppsala, Sweden

    These authors were joint senior authors on this work.

    X
  • Manfred W. Kilimann mail

    manfred.kilimann@neuro.uu.se

    Affiliation: Molecular Cell Biology Unit, Department of Neuroscience, Uppsala University, Uppsala, Sweden

    These authors were joint senior authors on this work.

    X
  • Published: March 15, 2012
  • DOI: 10.1371/journal.pgen.1002568

Abstract

Neurobeachin (Nbea) regulates neuronal membrane protein trafficking and is required for the development and functioning of central and neuromuscular synapses. In homozygous knockout (KO) mice, Nbea deficiency causes perinatal death. Here, we report that heterozygous KO mice haploinsufficient for Nbea have higher body weight due to increased adipose tissue mass. In several feeding paradigms, heterozygous KO mice consumed more food than wild-type (WT) controls, and this consumption was primarily driven by calories rather than palatability. Expression analysis of feeding-related genes in the hypothalamus and brainstem with real-time PCR showed differential expression of a subset of neuropeptide or neuropeptide receptor mRNAs between WT and Nbea+/− mice in the sated state and in response to food deprivation, but not to feeding reward. In humans, we identified two intronic NBEA single-nucleotide polymorphisms (SNPs) that are significantly associated with body-mass index (BMI) in adult and juvenile cohorts. Overall, data obtained in mice and humans suggest that variation of Nbea abundance or activity critically affects body weight, presumably by influencing the activity of feeding-related neural circuits. Our study emphasizes the importance of neural mechanisms in body weight control and points out NBEA as a potential risk gene in human obesity.

Author Summary

Body weight and energy balance are under very complex neural, endocrine, and metabolic control. Correspondingly, recent research suggests that hundreds of genes contribute to human obesity and that only a small proportion of them have as yet been identified. Neurobeachin (Nbea) is a protein specifically expressed in nerve and endocrine cells and is important for neurotransmission, apparently by influencing the synaptic targeting of membrane proteins. Here, we show that heterozygous knockout mice, expressing Nbea at 50% of normal levels, display increased adipose tissue mass, abnormal feeding behavior, and modified expression of specific genes in the brainstem and hypothalamus known to be important for body weight control. Moreover, we find that NBEA gene polymorphisms are associated with body-mass index in adult and juvenile human cohorts. Our results demonstrate that variation of Nbea activity critically affects body weight, presumably by influencing the activity of feeding-related neural circuits. They emphasize the importance of neural mechanisms in body weight control, and they identify NBEA as a potential genetic risk factor in human obesity.

Introduction

The BEACH (beige and Chediak-Higashi) domain protein family is implicated in the intracellular targeting of membrane proteins. Its members have been found in yeasts, amoebas, plants and animals, suggesting involvement in fundamental cellular functions. Mutations in BEACH domain proteins result in complex defects of cellular membrane dynamics and membrane protein targeting [1][5].

One of the eight mammalian BEACH proteins [5] is Neurobeachin (Nbea), a 327-kDa molecule expressed in neurons and endocrine cells. Nbea contains a high-affinity binding site for the type II regulatory subunit of protein kinase A (PKA) [6], which classifies it as an A-kinase anchor protein (AKAP). AKAPs anchor and concentrate the PKA holoenzyme at defined subcellular locations, enhancing the efficiency and specificity of the interaction of PKA with selected subsets of its target proteins [7].

Nbea is associated with polymorphic vesiculo-tubulo-cisternal endomembranes and postsynaptic plasma membranes, and it is found at high concentrations near the trans side of Golgi stacks. Therefore, a role of Nbea in the post-Golgi sorting or targeting of membrane proteins was proposed [6]. Nbea is essential for synaptic neurotransmission at neuromuscular junctions (NMJ): Nbea-null mice generated via coincidental insertion mutagenesis die immediately after birth due to breathing paralysis caused by a complete block of evoked transmission at NMJs [8]. In independently derived Nbea KO mice, central neurons showed impaired neurotransmission at both excitatory and inhibitory synapses, lower synapse density and altered synaptic protein composition while the lethal NMJ phenotype was also confirmed. The electrophysiological phenomena at central synapses suggested defects of both presynaptic neurotransmitter release and postsynaptic response, e.g., through reduced neurotransmitter receptor density [9].

Human data on NBEA are very limited, but heterozygous disruptions in the NBEA gene have been linked with autism and multiple myeloma. A de novo translocation in the NBEA gene was detected in an autistic patient [10], and additional evidence linking deletions of the chromosomal region containing NBEA to autism has been found ([11]; OMIM 608049). Heterozygous deletions involving NBEA were found in a subgroup of multiple myeloma patients [12], and NBEA was shown to harbor a region of enhanced chromosomal fragility [11], [13].

Homozygous inactivation of the Nbea gene in mice results in perinatal death, whereas heterozygous Nbea KO mice are viable and fertile and do not display obvious abnormalities. The association of heterozygous human NBEA mutations with autism and cancer suggested that NBEA haploinsufficiency may produce related phenotypes in mice, and we therefore investigated Nbea+/− mice in the phenotyping screen of the German Mouse Clinic (GMC). While the possible involvement of Nbea in autism and cancer requires further study, we unexpectedly found phenotypic features of these mice implicating Nbea in energy balance regulation: significantly greater body weight and adipose tissue mass and an elevated energy surplus during early life. Subsequently, we detected alterations in feeding behavior of Nbea+/− mice in several functional tests investigating the effects of high caloric and highly palatable diets, and in the expression of feeding-related genes in the hypothalamus. Finally, we detected the association of two intronic NBEA single-nucleotide polymorphisms (SNPs) with weight and body mass index (BMI) in humans, suggesting that variability within the NBEA gene may be a genetic risk factor in human obesity.

Results

Haploinsufficient Nbea+/− mice on standard chow display faster increase in body weight due to moderately elevated adiposity

The Nbea gene-trap KO allele has been described [9]. Mice heterozygous for this allele are viable and fertile and display no obvious abnormalities in observation up to an age of 2 years. We did not observe the dwarfism described by Su et al. [8] for their Nbea+/− mice. This phenotypic aspect of the mutants of Su et al. may be due to the specific nature of their mutation (antisense-oriented insertion of a growth hormone minigene). Immunoblot analysis of brain homogenates showed that Nbea protein expression in Nbea+/− mice was ~50% of wild-type (WT) mice (42±6% [mean±SEM], n = 12) whereas the expression level of the Nbea isoform, Lrba, was unaffected (Figure 1A).

thumbnail

Figure 1. Nbea-haploinsufficient mice develop higher body weight due to higher adipose tissue mass.

(A) Western blot analysis of whole brain demonstrates that Nbea protein expression in Nbea+/− mice is half of that in WT mice. The same blot was sequentially developed with anti-Nbea, anti-Lrba and anti-Cadherin. 1, ½ and ¼ indicate a dilution series of loaded protein. (B) Male and female Nbea+/− mice develop higher body mass than WT controls. From week 14 on we continuously detected a significant genotype effect on body mass in males and females combined (week 14–15 p<0.05, week 16–19 p<0.01, afterwards p<0.001). (C,D) qNMR scans of mice aged 6–22 weeks shows that increased body mass of Nbea+/− mice is caused by increased fat tissue mass (significant genotype effect in females between week 6–21, in males in week 13–16, linear model with body mass as covariate). (E) The in-out-difference between daily metabolizable energy and daily energy expenditure was significantly increased in Nbea+/− mice at the age of 8 weeks. (F) Plasma insulin and (G) leptin at 22 weeks of age were significantly increased in Nbea+/− mice. (H,I) High-fat feeding from age 14 weeks accelerates weight gain, more pronouncedly in Nbea+/− than in WT mice. * within males, +within females, P<0.05; ** within males, ++within females, P<0.01; *** within males, +++within females, P<0.001; error bars, ± SEM. In part H, all genotype differences were significant for males with at least P<0.05 (except weeks −2 and 7, n.s.) and for females with at least P<0.001 (except week −2, p<0.01).

doi:10.1371/journal.pgen.1002568.g001

Nbea+/− mice were systematically analyzed for genotype effects in the primary phenotyping screen at the GMC. Mutant and control mice entered the screen at an age of 9 weeks and were consecutively investigated in the behavior, neurology, dysmorphology, clinical chemistry and energy metabolism screen, among others [14][15]. Both male and female mutant mice were slightly but significantly heavier than controls. Dual-energy X-ray absorptiometry (DXA) performed on 16 weeks old WT and Nbea+/− mice revealed that the difference in body weight was due to increased body fat content (Table 1). This increased adiposity was apparent in both females and males.

thumbnail

Table 1. First-line phenotyping in the German Mouse Clinic: Body composition (DXA) and energy assimilation parameters of 18–20 week-old WT and Nbea+/− mice, fed with standard chow ad libitum over 5 days (n = 7/group for energy metabolism, n = 15/group for DXA; means±SD).

doi:10.1371/journal.pgen.1002568.t001

As part of the first-line phenotyping screen we then determined food intake and efficiency of energy extraction from the diet in cohorts of 7 mice over 5 days at the age of 18–20 weeks, with ad libitum access to standard chow (Table 1). At this stage food intake was higher in Nbea+/− mice (p<0.05) but proportional to body mass; if initial body mass was included as a covariate, the statistical analysis detected no genotype effect on food intake. The overall efficiency of energy extraction from food (food assimilation coefficient) did not differ between genotypes. Daily metabolized energy intake was indistinguishable between the two genotypes when adjusted for body weight.

Behavioral analysis of spontaneous activity in a novel environment, measured by the modified Hole Board test at age 8–9 weeks, and neurological analysis according to a modified SHIRPA protocol at age 9–10 weeks, did not indicate reduced spontaneous activity that could cause lower energy expense of the Nbea+/− mice. In particular, no reductions of motor activity parameters (e.g., total distance moved) were detected. The only genotype-related abnormality was a slight increase of mean locomotion velocity in both sexes by an average 6.5% (genotype effect, p<0.05), which may indicate a minor perturbation of the locomotor rhythm generator and would, if at all, cause an increased energy expense.

Blood chemical parameters determined at the ages of 12–13 and 17–18 weeks yielded a slightly increased α-amylase activity in both sexes by an average 8% as the only parameter significantly (p<0.05) and reproducibly abnormal in the mutants (age 12–13 weeks: males, WT 2640±90 vs. Nbea+/−2790±60; females, WT 1940±50 vs. Nbea+/− 2130±40; in U/L±SEM). Sodium, potassium, calcium, chloride, inorganic phosphate, creatinine, triglycerides, cholesterol, urea, uric acid, glucose, total protein, creatine kinase, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, ferritin, transferrin and lipase were unaffected by genotype.

In a second cohort of mice we monitored body mass and body composition weekly during early lifetime. We could confirm the development of mild obesity both in Nbea+/− males and females (Figure 1B–1D). To evaluate daily energy balance, we monitored both sides of the energy balance equation, i.e. food intake and energy assimilation and energy expenditure, by gas exchange measurements over 24 hours at eight weeks of age. Indirect calorimetry did not reveal statistically significant differences in daily energy expenditure (Table 2). Monitoring of food intake and bomb calorimetry of feces and diet samples to determine caloric uptake and the amount of metabolizable energy indicated that energy uptake was slightly increased in mutant animals but the difference did not reach statistical significance when analyzed by a linear regression model including genotype, sex and body mass (Table 2). Calculating the difference between daily metabolizable energy and daily energy expenditure showed that both WT and Nbea+/− mice were in a positive energy balance at 8 weeks of age (Table 2 and Figure 1E). In WT mice this surplus of energy, expressed as in-out difference in Table 2, was in the range of ~15 kJ per day reflecting the normal energy demand for growth in 8 weeks old mice. Notably, the surplus of energy in Nbea+/− mice was slightly higher with ~18 kJ per day. When compared to WT mice, Nbea+/− mice had 3.2 kJ (females) and 3.4 kJ (males) excess energy available on a per day basis (Table 2). This effect of genotype was significant when body mass changes during the indirect calorimetry trial were included in the linear regression model. Continuous monitoring of spontaneous motor activity (distance traveled, rearing) and determination of body temperatures again ruled out both parameters as explanations for the increased fat mass and positive energy balance of Nbea+/− mice (Table 2). Plasma insulin (males +146%, females +29%, genotype p = 0.013) and leptin levels (males +122%, females +131%, genotype p = 0.002), determined at 22 weeks of age, were significantly increased in Nbea+/− mice (Figure 1F, 1G). When adjusted for body fat content, however, no difference in leptin levels could be detected. Resistin and PAI-1 were not different between genotypes.

thumbnail

Table 2. Energy balance and motor activity of 8 week-old WT and Nbea+/− mice, fed with standard chow ad libitum over 24 h (n = 8/group; mean±SD).

doi:10.1371/journal.pgen.1002568.t002

Several mouse models for obesity exhibit normal or only slightly increased body weight on standard diets but develop increased adiposity in response to high-fat (HF) diet intake [16]. Therefore, Nbea+/− and WT mice were fed a HF diet (60 energy% fat) from the age of 14 weeks. In this third cohort of mice, Nbea+/− males and females weighed, respectively, 2.0 g and 3.6 g more than WT mice at the onset of HF feeding, again confirming the body mass phenotype. In response to HF feeding, Nbea+/− females, in particular, exhibited increased susceptibility to diet-induced obesity. After 7 weeks of HF feeding Nbea+/− females gained substantially more weight than WT (4.1 g), whereas the differential weight gain of Nbea+/− males in excess of WT was marginal (0.6 g) (Figure 1H, 1I). A glucose tolerance test after 22 weeks revealed no genotype effects on baseline glucose level or glucose response, in males or females (not shown).

Nbea+/− mice overeat when motivated by hunger or by the diet's incentive combination of energy and palatability, but not by palatability alone

As the previous experiments detected mild differences in gross energy balance between Nbea+/− and WT mice, we tested for more subtle modifications of feeding behavior in episodic feeding paradigms. During these tests, male mice were between the 8th and 10th week of age, before the emergence of a statistically significant body weight difference between the genotypes. Although, at this age, Nbea+/− mice did not consume detectably more standard chow when fed ad libitum (Nbea+/−: 174.8±1.0 g/kg body weight; WT: 177±2.3 g/kg body weight), the combined incentive of high calorie content and palatability of a high-fat/high-sugar (HFHS) diet stimulated them to eat significantly more than WT controls (Figure 2A). When refed after overnight food deprivation, Nbea+/− mice ingested more also of the standard chow (Figure 2B). Similarly, daily consumption of caloric palatable fluids (Intralipid fat emulsion, sucrose, glucose, fructose) was higher in Nbea+/− than in WT mice (Figure 2C). In contrast, non-caloric yet palatable tastants (saline, saccharin, sucralose) were not overconsumed by the Nbea+/− animals (Figure 2D).

thumbnail

Figure 2. Differential feeding behavior of Nbea+/− and WT mice.

Male mice were tested at the age of 8–10 weeks, prior to the manifestation of a significant body weight difference between the genotypes. Compared to WT mice, Nbea+/− mice (A) ate more ad libitum of the energy-dense and palatable high-fat high-sugar (HFHS) solid diet; (B) ate more standard chow upon 2-h refeeding after overnight food deprivation; (C) consumed more of the caloric and palatable 4.1% Intralipid, 10% sucrose, 10% glucose and 10% fructose solutions; but (D) they consumed the same amounts of tastants which do not contain calories, i.e. saline, 0.1% saccharin or 0.05% sucralose, despite their palatability. Nbea+/− mice (E) were not resistant to leptin, but they were (F) more sensitive to the anorexigenic naltrexone (NTX) than their WT counterparts. *, P<0.05; **, P<0.01; ***, P<0.001; error bars, ± SEM.

doi:10.1371/journal.pgen.1002568.g002

Nbea+/− mice are leptin-responsive and naltrexone-hyperresponsive

Obesity may be caused by leptin resistance. Resistant animals injected with leptin prior to a meal do not reduce food consumption. When we treated overnight-deprived Nbea+/− mice with leptin at the time of chow refeeding, they ate significantly less food than control animals receiving only saline injection (Figure 2E), indicating that leptin resistance is unlikely to explain the obesity of Nbea+/− mice. Resistance to leptin is also marked by the lack of responsiveness of hypothalamic neurons, which relay the effects of leptin at the central level, to hormone infusion. A preliminary c-Fos induction experiment (Figure S1) showed that leptin infusion increased the density of Fos-immunopositive, activated neurons in the arcuate nucleus (ARC) of an Nbea+/− and a WT mouse alike, confirming that the mutant mice are sensitive to leptin.

An anorexigenic dose of the opioid receptor antagonist, naltrexone (NTX), administered peripherally to overnight-deprived mice just prior to chow refeeding, caused a ~30% reduction in food intake in WT animals. Nbea+/− mice consumed ~60% less food than saline controls (Figure 2F), showing that they are responsive to NTX, indeed even hyperresponsive (p = 0.04).

Hypothalamic expression of genes involved in feeding regulation differs between Nbea+/− and WT mice in the baseline sated state and in the hungry state, but not upon intake of palatable foods

Following the identification of altered feeding behavior described above, we hypothesized that reduced Nbea expression may alter the activity of neuronal networks involved in energy balance control. We investigated whether expression of feeding-related genes differs between the Nbea+/− and WT genotypes in response to different food availability/quality regimens: in ad libitum feeding of standard chow, following food deprivation, and when a palatable diet is offered. Ad libitum-fed Nbea+/− mice expressed a higher level of orexigenic dynorphin (DYN) mRNA compared to WT controls in the hypothalamus (Figure 3A). Moderate-length (16 h) food deprivation led to higher mRNA expression of four hypothalamic genes in Nbea+/− vs. WT mice. Three of them: DYN, proopiomelanocortin (POMC) and opioid-like receptor-1 (ORL1), are linked with orexigenic responses (POMC gives rise to orexigenic beta-endorphin, but also to hypophagic melanocortins (MC)), whereas corticotropin releasing hormone (CRH) is involved in the HPA axial activity and satiety signaling. In the brainstem, only the MC3 receptor mRNA level was lower in Nbea+/− than in WT mice in the ad libitum paradigm, and none of the markers were differentially affected by food deprivation (Figure 3B). Animals exposed to the palatable diet did not show any difference between genotypes in their gene expression response in the hypothalamus (Figure 3C).

thumbnail

Figure 3. Differential expression of feeding-related genes in Nbea+/− and WT mice under different feeding paradigms.

Ad libitum-fed, sated Nbea+/− and WT mice showed a differential expression of the dynorphin (DYN) mRNA in the hypothalamus (A) and of the melanocortin (MC) receptor-3 mRNA in the brainstem (B). 16-h food deprivation differently affected expression of mRNAs encoding DYN, proopiomelanocortin (POMC), opioid-like receptor-1 (ORL1) and corticotropin releasing hormone (CRH) in the hypothalamus (A), whereas no differences between the genotypes were triggered by food deprivation in the brainstem (B). Exposure to the palatable HFHS diet did not affect gene expression differently in the Nbea+/− and WT animals. Only DYN mRNA was increased in the standard chow-fed controls (C). * P<0.05; error bars, ± SEM. The following other genes were also analyzed, but their expression levels did not differ between the genotypes: AGRP, Agouti-related protein; AVP, vasopressin; CCK, cholecystokinin; CRHR, CRH receptor; DOR, delta opioid receptor; ENK, enkephalin; GHSR, growth hormone secretagogue receptor; GLP1R1, glucagon-like peptide 1 receptor 1; KOR, kappa opioid receptor; MCH, melanin concentrating hormone; MOR, mu opioid receptor; NPY, neuropeptide Y; ORX, orexin.

doi:10.1371/journal.pgen.1002568.g003

NBEA gene polymorphism is associated with body-mass index (BMI) in human cohorts

We then examined whether the link between Nbea and body weight control identified in the mouse model can be extended to humans. We studied the association of two relatively common SNPs with body weight and BMI. Two intronic SNPs in NBEA, rs17775456 and rs7990537 (r2 = 0.12), were genotyped in two cohorts: one comprising adult men from the ULSAM cohort and one case-control cohort of children and adolescents. Table 3 shows anthropometric characteristics in the two cohorts according to NBEA rs17775456 and rs7990537 genotype and weight status. None of the two SNPs caused deviation from Hardy-Weinberg equilibrium in any of the studied cohorts (p>0.05). We analyzed the subjects for associations with overweight and obesity depending on NBEA genotypes (Table 4) as well as BMI and weight as continuous traits (Table 5). We found a significant association for rs17775456 and rs7990537 with BMI as a continuous trait (rs17775456: p = 0.001 and rs7990537: p = 0.006) and trends for weight (rs17775456: p = 0.022 and rs7990537: p = 0.025) among the overweight adult men. Carriers of the minor allele were heavier and had higher BMI than non-carriers. Among children and adolescents, we found that rs7990537 was significantly associated with BMI in the normal-weight children, the carriers of the minor allele again having higher BMI standard deviation scores (SDS).

thumbnail

Table 3. Anthropometric characteristics in 50 year-old men and children stratified according to weight status and NBEA rs17775456 and rs7990537 genotype.

doi:10.1371/journal.pgen.1002568.t003
thumbnail

Table 4. Odds ratio for overweight and obesity depending on NBEA genotypes in adults and children.

doi:10.1371/journal.pgen.1002568.t004
thumbnail

Table 5. Association with BMI and body weight as continuous traits in adults and children for NBEA rs17775456 and rs7990537.

doi:10.1371/journal.pgen.1002568.t005

Discussion

For years, obesity research focused primarily on ligand-receptor interactions as the basis of feeding and metabolic responses. Consequently, improper functioning of the ligand-receptor system was considered a causative factor underlying dysregulation of body weight. While this holds true for many such systems, including melanocortins, leptin, ghrelin and neuropeptide Y [17][20], it has become clear that molecules which are not directly involved in communication at the cell surface, but are part of intracellular mechanisms, e.g., the nucleic acid demethylase Fto, also play a crucial role in the control of energy homeostasis [21]. Here, we report a combination of mouse and human data pertaining to Nbea, a regulator of membrane protein trafficking, showing that mice heterozygous for the Nbea KO allele develop an obese phenotype and that two intronic NBEA SNPs are associated with weight and BMI in humans. Nbea is one of a growing number of proteins important for synaptic development and function that is also associated with obesity. Changes in the Nbea status appear to affect select metabolic and feeding-related parameters.

Nbea+/− mice develop moderately elevated body weight during early adulthood. Body composition analyses show that this higher body weight stems from increased adipose tissue mass. Lean mass is virtually unaffected (slightly lower in the experiment of Table 1, slightly higher in the experiment of Figure 1D), suggesting altered partitioning of energy in these animals in favor of energy preservation and storage. Therefore, the phenotype of the Nbea+/− mouse can be defined as mildly obese. Increased insulin levels are consistent with this phenotype. Clinical chemistry parameters were otherwise unremarkable, except for a small increase of α-amylase activity in plasma. Leptin levels in Nbea+/− mice were increased only in proportion to the higher body fat content, and these animals were not leptin-resistant just prior to the onset of the overweight phenotype, as demonstrated by their hypophagia and c-Fos induction in response to leptin administration. At the age of 16 to 18 weeks Nbea+/− mice fed ad libitum consumed standard chow in greater quantities and exhibited higher daily metabolizable energy intake as compared to WT mice (Table 1), but only in proportion to body mass [22]. Reduced locomotor activity or body temperature as possible explanations of weight gain could not be detected, neither in the primary phenotyping (Table 1) nor in the experiment of Table 2. Rather, also in additional measurements, body temperature always tended to be increased. Taken together, our primary screen data did not reveal an explanation for the development of mild obesity in Nbea+/− mice.

Metabolic abnormalities in mildly obese mice, such as Nbea+/−, are very small and difficult to detect in whole body energy balance studies. It has been pointed out that the statistical power required to detect a slight but relevant imbalance between energy intake and expenditure is usually not attained with the small cohort sizes used in most animal experimentation [23]. We therefore conducted a second, more detailed analysis of whole body energy balance in a new cohort of mice just before the emergence of increased body fat accumulation. Energy assimilation and energy expenditure were monitored in parallel, but neither parameter as such was significantly altered. However, we found a small but significant elevation of the in-out difference of both parameters in Nbea+/− as compared to WT mice. In terms of absolute surplus energy gain the higher in-out-difference of about 3 kJ per day in Nbea+/− mice is sufficient to build up excess fat stores of about 1 g over less than two weeks [23].

Notably, an increased drive to consume food was revealed in the Nbea+/− mice by presenting them with a defined meal of standard chow following a single period of mild food deprivation. Nbea+/− animals ingested significantly more calories than WTs even though no detectable difference in body weight between the mutant and WT animals had as yet developed. Therefore heterozygotes have a higher baseline consumption reflecting their elevated body weight and additionally, under certain food availability conditions, they are more prone to episodic overeating that exceeds the body weight-adjusted control values. In line with this, our data on liquid diet intakes indicate that Nbea+/− animals, regardless of their energy status (i.e., hungry or sated), episodically overconsume tastants providing energy, as evidenced by our finding that non-deprived heterozygotes ingest more calorie-containing solutions of sucrose, glucose, fructose or a lipid emulsion (Intralipid) than WTs. An increase is also observed upon ad libitum exposure to high-fat high-sugar chow. It is important to note that this elevated intake of solid and liquid diets does not appear to be primarily driven by an increased response to food reward. While palatability serves as a co-stimulus to ingest food, the absence of calories prevents heterozygotes from consuming more than WTs even when the level of feeding reward is high, as Nbea+/− and WT mice did not differ in the amount of ingested non-caloric tastants, including palatable saccharin, sucralose and saline.

As Nbea has been shown to be involved in development of and neurotransmission within brain networks [9], we investigated the potential influence of Nbea haploinsufficiency on brain mechanisms pertaining to energy balance. Our gene expression data suggest changes in the activity of the circuitry governing energy homeostasis. Sated Nbea+/− animals overexpress orexigenic DYN in the hypothalamus. This may predispose them to eating more upon exposure to caloric foods of desirable characteristics (e.g., palatability, texture). An increased sensitivity of Nbea+/− mice to naltrexone in the feeding model strengthens the link between the opioid system and dysregulation of energy balance in Nbea haplosufficiency. DYN, which mediates maintenance of feeding as well as reward [24], [25], is a plausible candidate for such a function. Negative energy balance induced by food deprivation led to increased expression of as many as four hypothalamic genes in Nbea+/− compared to WT mice. Two of them, DYN and ORL1, encode orexigens [24], [26], [27]. This suggests an enhanced sensitivity of the hypothalamic feeding circuitry to calorie deprivation in Nbea+/− mice, associated with upregulated expression of neuropeptides which stimulate feeding. Since POMC codes for anorexigenic melanocyte stimulating hormone, changes in its expression may also reflect a compensatory mechanism in response to a positive energy balance in the mutant. In contrast to the findings in the deprived and sated state, exposing animals to the palatable diet did not cause differential expression of any gene between Nbea+/− and WT mice in the hypothalamus.

We searched HapMap (www.hapmap.org) for SNPs in the human NBEA gene with the aim to genotype a frequent SNP as well as a rare SNP that could have a higher penetrance than a common SNP. NBEA is a large gene, ~730 kb, and based on HapMap data the gene contains over 30 haplotype blocks. The two SNPs we selected, rs17775456 and rs7990537, are part of two separate haplotype blocks spanning around 261 and 54 kb, respectively. These SNPs were genotyped in two cohorts: one consisting of severely obese Swedish children and adolescents (mean age 12.6±3.3 years and mean BMI SDS 6.2±1.4) and their age-matched normal-weight controls, and another one of Swedish men born 1920–1924, thus reaching adulthood prior to the appearance of today's obesogenic environment. Individuals in both cohorts showed a significant association of NBEA polymorphism with BMI. We found associations for both, rs17775456 and rs7990537, with both body weight and BMI in overweight adult men, while one of the SNPs showed association with BMI in the normal-weight children. In both cohorts, the same allele was associated with high BMI. No genetic variants in NBEA have previously been reported to be associated with obesity. However, one of the latest papers on novel loci for BMI [28] estimates that there are at least an additional 300 undiscovered variants that can be linked to obesity. In addition, according to data on 1479 subjects from the British 58 Birth Cohort (www.b58cgene.sgul.ac.uk/index.php) six SNPs in the two haplotype blocks harboring our SNPs are nominal associated with BMI at the age of 44–45 with the same effect direction. This suggests that NBEA may be linked to a moderately adipogenic activity which, in children, is better detectable in a normal-weight than in a severely obese background, and only manifests as overweight at an adult age.

We conclude that neural circuitries involved in food intake and body weight control are sensitive to moderate variation of Nbea activity such as haploinsufficiency. Morphological and electrophysiological abnormalities of cortical neurons have indeed been detected in Nbea+/− mice [29]. The reduction of Nbea expression by only 50% suffices to cause monogenic adiposity, at least in the mouse model and the C57BL/6N genetic background. This points out human NBEA as a potential genetic factor in common, polygenic obesity in collusion with additional genes. Even more subtle variations of NBEA expression, activity or regulation may contribute to polygenic obesity, as a risk or protective factor. The NBEA gene is very large (730 kb, 58 exons) and recombination-prone [13], offering extensive mutation potential.

Recent genome-wide association studies emphasize the high proportion of neuronally expressed genes implicated in obesity. Indeed, human obesity has been characterized as “a heritable neurobehavioral disorder that is highly sensitive to environmental conditions” [30]. Our characterization of the obese Nbea+/− phenotype is a case in point for both parts of this statement. Nbea is expressed in apparently all neuronal and endocrine cell types [6] and probably has a broad importance for nervous system development and function [9]. In spite of this pleiotropy, the first macroscopic manifestation of Nbea haploinsufficiency to be detected in mice is an impact on body weight, reflecting the subtlety and vulnerability of the neural control of energy balance. Moreover, our findings that the Nbea+/− mice are more prone than WT mice to respond to episodic feeding paradigms by overconsuming can be seen as a perturbed ability to handle nutritional challenges, an important factor also in human obesity.

It is intriguing that heterozygous perturbations of the NBEA gene have been linked to three dissimilar medical conditions: autism, multiple myeloma, and now obesity. Whereas involvements in autism and obesity may be explained by impacts of NBEA underexpression on the development or functioning of different neuronal circuitries, the association with cancer may be due to functional overlap with its ubiquitous isoform, LRBA [31]. It seems to be a common feature of BEACH proteins that they are involved in the targeting of multiple membrane proteins, and that their KOs therefore generate pleiotropic but partial defects [9]. Autism, cancer and obesity all are typical polygenic disorders, and in combination with different sets of additional risk genes, NBEA misexpression may contribute to different manifestations.

Materials and Methods

Animals

Construction and genotyping of the Nbea gene-trap KO mice has been described [9]. Analyses described here were performed with animals after backcrossing into the C57Bl/6N background for 5 generations or more. Animal experiments were performed at the animal facilities of Uppsala University or the GMC at the Helmholtz Zentrum München, Germany. All studies received prior approval from the local animal ethics committees and adhered to the German, Swedish and EU laws pertaining to the protection of animals.

Western blot analysis of Nbea expression

Immunoblots of 5% SDS-polyacrylamide gels were sequentially probed with affinity-purified rabbit sera directed against isoform-specific sequences of mouse Nbea and mouse Lrba generated in our laboratory (S.S. & M.W.K.), and with an anti-pan-cadherin mAb (Sigma C1821). Chemiluminescence-exposed X-ray films were analyzed by densitometry. Whole-brain homogenates were prepared from four animals of each genotype (aged 6 months), adjusted for equal protein concentrations, and dilution series of all four sample sets were analyzed twice by Western blotting and densitometry. Nbea and Lrba signals of each lane were normalized on the respective cadherin control signal.

Body composition, energy metabolism, and clinical chemistry

Metabolic functions of WT and Nbea+/− mice were characterized in a comprehensive systemic phenotyping screen [14], [15]. In total, 140 mice entered the GMC in three cohorts. The primary screen was conducted using the first cohort of 60 mice (n = 15 per sex and genotype for clinical chemistry [tested at 12–13 and 17–18 weeks] and DXA [age, 16–18 weeks]; a subsample of n = 7 mice per sex and genotype in the energy metabolism screen). Groups of up to four mice per cage were housed on a 12-h light/dark cycle, had ad libitum access to regular laboratory chow (Altromin1324; Altromin, Lage, Germany), and were provided with UV-irradiated and micro-filtered tap water. For energy assimilation monitoring (age 18–20 weeks), mice were single-caged on grid panels (0.5-cm grid hole diameter) allowing the collection of feces and spilled food of individual mice. Body weight, food consumption, mean rectal body temperature of five consecutive measurements conducted at 10 a.m. every day, daily feces production calculated from a five-day pooled sample, energy uptake, energy content of the feces, metabolizable energy and the food assimilation coefficient were determined. Samples of the lab chow and feces (~1 g) were dried at 60°C for two days, homogenized in a grinder and squeezed to a pill for determination of energy content in a bomb calorimeter (IKA Calorimeter C7000). Energy uptake was determined as the product of food consumed and the caloric value of the food. To obtain metabolizable energy, the energy content of feces and urine (2% of energy uptake) was subtracted from energy uptake. Two-way ANOVA (SigmaStat, Jandel Scientific) was used to test for effects of the factors, genotype and sex. To adjust for body mass differences in energy metabolism parameters, a linear regression model was applied including body mass as a co-variate (TIBCO Spotfire S+ 8.1 for Windows). A pDEXA Sabre X-ray Bone Densitometer (Norland Medical Systems Inc., Basingstoke, Hampshire, UK) was used for dual-energy X-ray absorptiometry (DXA). The entire body area including and excluding the skull was assayed with a 0.02-g/cm2 Histogram Averaging Width (HAW) setting.

In the second cohort of mice (n = 10 per sex and genotype), body composition was followed up by non-invasive qNMR scans (MiniSpec LF60, Bruker Optics, Germany). For the evaluation of energy balance, single mice were kept in respirometry cages (Phenomaster System, TSE Systems, Germany) including the monitoring of gas exchange, food and water uptake, and locomotor activity. To convert food consumption into caloric uptake, energy extraction efficiency of individual mice was determined as described above. Li-heparin plasma samples for clinical chemistry analyses were obtained by blood collection from the retroorbital vein plexus of ether-(first cohort) or isoflurane-anesthetized mice into heparinized tubes. Samples were mixed thoroughly and stored for 2 h at room temperature before being separated from blood cells by centrifugation (4656× g; 10 min). Plasma samples were stored at 4°C and analyzed within 24 h using an AU400 autoanalyzer (Olympus, Hamburg, Germany) and adapted test kits from Olympus. Adipokine determinations were performed with the LINCOplex mouse serum adipokine multiplex immunoassay kit MADPK-71K-07. Two-way ANOVA (SigmaStat, Jandel Scientific) was used to test for effects of genotype and sex, and significance of mean differences between genotypes within each sex was tested using the Welsh t-test (Excel, Microsoft).

HF feeding and glucose tolerance test

Beginning at the age of 14 weeks, a third cohort of mice (n = 10 per sex and genotype) were fed a HF diet (D12492, Research Diets, New Brunswick NJ, USA) for further 24 weeks. 60% of the total energy content (23.2 kJ g−1) was due to fat (lard and soybean oil). Mice were weighed every week. After 22 weeks, an intraperitoneal glucose tolerance test was conducted after overnight fasting according to the EMPReSSslim protocol (www.eumodic.eu). Blood samples were taken from the tail vein prior, 15, 30, 60, 90, and 120 minutes after intraperitoneal injection of the 2 mg per g body mass glucose bolus.

Episodic feeding experiments

Animals were housed individually in a temperature- (21–23°C) and humidity-controlled facility with a 12:12 LD cycle (lights on at 06:00). Age-matched (±2 days) males were used simultaneously. Tap water and standard chow (Lactamin, Lidköping, Sweden) were available ad libitum unless specified otherwise. Sixteen age-matched animals of each genotype were used in Experiments 1, 2 and 3, whereas 11 mice per genotype were included in Experiment 4. Mice were between the 8th and 10th week of age, before the emergence of a statistically significant difference in body weight between the genotypes: 18.0±0.4 g in heterozygotes and 17.5±0.3 g in WT controls.

Experiment 1: Effect of genotype on ad libitum consumption of the energy-dense and palatable HFHS (high-fat high-sugar) diet.

Standard chow was removed from cages at 09:00 and it was replaced with the palatable HFHS pellets (Research Diets). During the first 24 h of exposure to the HFHS food, the animals were allowed to get accustomed to the new diet. Then the amount of ingested food (corrected for spillage) was measured for the period of 24–72 h.

Experiment 2: Effect of genotype on food deprivation-induced re-feeding.

Standard chow was removed just before the onset of darkness and it was returned at 10:00 on the subsequent day. The amount of ingested food (corrected for spillage) was measured 2 h later when the major consummatory activity had subsided.

Experiment 3: Effect of genotype on ad libitum consumption of caloric and palatable Intralipid and sugar solutions.

Mice were given a bottle of 10% sucrose, 4.1% Intralipid, 10% glucose or 10% fructose in addition to chow for 48 h. Intralipid (Fresenius, Sweden), a palatable lipid emulsion of soybean oil, glycerol and egg yolk phospholipids, has been used in experiments utilizing liquid diets [32]. Sucrose, glucose, fructose and Intralipid were isocaloric (0.4 kcal/g), whereas the energy content of chow was 3.6 kcal/g. During the first 24 h of exposure to the liquids, the animals were allowed to get accustomed to the new tastants. Uptake was measured during the following 24 h.

Experiment 4: Effect of genotype on ad libitum consumption of non-caloric but palatable saccharin, sucralose, and saline solutions.

Mice were given a bottle of 0.1% saccharin, 0.05% sucralose or saline in addition to chow for 48 h. Total caloric intake per mouse in the saccharin paradigm in heterozygotes was 12.53±0.7 kcal and in WTs, 13.39±0.5 kcal; in the sucralose paradigm, heterozygotes ingested 14.89±0.7 kcal and WTs, 14.53±0.5 kcal; in the saline paradigm, heterozygotes ingested 13.19±0.4 kcal and WTs, 13.25±0.5 kcal. During the first 24 h of exposure to the liquids, the animals were allowed to get accustomed to the new tastants.

Experiment 5: Effect of leptin administration on deprivation-induced food intake by Nbea+/− mice.

Chow was removed from the hoppers of Nbea+/− mice before the onset of darkness. On the next day, at 11:00, the animals were injected i.p. with 10 µg leptin or vehicle (n = 5/group) and the pre-weighed food pellets were returned to the hopper. Food intake was measured 3 h post-injections and corrected for spillage.

Experiment 6: Effect of naltrexone (NTX) on deprivation-induced food intake.

Chow was removed from the hoppers of Nbea+/− and WT mice before the onset of darkness. On the next day, at 11:00, the animals were injected i.p. with 3 mg/kg NTX or vehicle (n = 5–7/group) and the pre-weighed food pellets were returned to the hopper. Food intake was measured 3 h post-injections and corrected for spillage.

Real-time PCR analysis of expression of feeding-related genes

Hypothalamic and brainstem gene expression after 16-h food deprivation.

Standard chow was removed just before the onset of darkness and mice (n = 8/genotype) were decapitated between 10:00 and 11:00 on the next day. The fed controls (n = 8/genotype) had food ad libitum and were decapitated between 09:00 and 10:00. mRNA expression in the hypothalamus and brainstem was studied with real-time PCR.

Hypothalamic Nbea expression following 48-h consumption of the HFHS diet.

Mice that had been pre-exposed 5 days earlier to the HFHS food (Research Diets) for 1 day were given this diet again for 48 h; controls (n = 8/genotype) had standard chow only. Mice were decapitated after 48 h (between 10:00 and 11:00). mRNA expression in the hypothalamus was studied with real-time PCR.

PCR methodology.

Brains were excised, anatomical regions of interest dissected, immersed in RNAlater (Ambion, USA), kept at room temperature for 2 h and, thereafter, stored at −80°C until further processed. Samples were homogenized and RNA prepared as previously described [33]. Relative expression levels of seven housekeeping genes (glyceraldehyde-3-phosphate-dehydrogenas​e,β-tubulin, ribosomal protein 19, histone H3, cyclophilin, β-actin, and succinate dehydrogenase complex subunit B) and of the genes of interest were determined with quantitative rtPCR. Each reaction, with a total volume of 20 µl, contained 20 mM Tris/HCl pH 9.0, 50 mM KCl, 4 mM MgCl2, 0.2 mM dNTP, DMSO (1:20) and SYBR Green (1:50000). Template concentration was 5 ng/µl and the concentration of each primer was 2 pmol/µl. Primers were designed with Beacon Designer (Premier Biosoft) using the SYBR Green settings. All rtPCR experiments were performed in duplicates; for each primer pair a negative control with water and a positive control with 5 ng/µl of genomic DNA were included on each plate. Amplifications were performed with 0.02 µg/ml Taq DNA polymerase (Biotools, Sweden) under the following conditions: initial denaturation at 95°C for 3 min, 50 cycles of denaturing at 95°C for 15 sec, annealing at 52.8–60.1°C for 15 sec and extension at 72°C for 30 sec. Analysis of rtPCR data was performed as previously reported [34]. MyIQ 1.0 software (Bio-Rad) was used. Primer efficiencies were calculated using LinRegPCR [35] and samples were corrected for differences in primer efficiencies. The GeNorm protocol described by Vandesompele et al. [36] was used to calculate normalization factors from the expression levels of the housekeeping genes. Grubbs' test was used to remove outliers. Differences in gene expression between groups were analyzed with ANOVA followed by Fisher's PLSD test where appropriate. P<0.05 was used as the criterion of statistical significance.

Human genetic studies

Subjects.

We genotyped 1152 men from the Uppsala Longitudinal Study of Adult Men (ULSAM), described previously [37][38]. The study was approved by the Ethics Committee of the Department of Medicine, Uppsala University. All participants gave their written informed consent. We further genotyped 1027 children and adolescents comprising one group of obese children and adolescents and one group of normal-weight adolescents, as described earlier [39]. The study was approved by the Regional Ethics Committee in Stockholm.

Phenotype characterization.

For the men, height was measured to the nearest whole centimeter and weight to the nearest whole kilogram at age 50 years. BMI was calculated as weight divided by height squared (kg/m2). For the children and adolescents, body weight and height were measured to the nearest 0.1 kg and 1 cm, respectively. BMI standard deviation score (BMI SDS) was calculated from weight and height and standardized for age and sex [40].

Genotyping.

Genotyping of NBEA rs7990537 and rs17775456 variants in the ULSAM cohort was carried out at the SNP technology platform at Uppsala University (http://www.genotyping.SE/) using an Illumina Golden Gate Assay [41]. The SNP genotype call rate in the samples was 96.8%. For the children and adolescents, genomic DNA was extracted from peripheral blood using QiaGen Maxiprep kit (Qiagen, Hilden, Germany). Genotyping was performed with pre-designed Taqman single-nucleotide polymorphism genotyping assay (Applied Biosystems, Foster City, USA) and an ABI7900 genetic analyzer with SDS 2.2 software.

Statistical analysis.

In order to test for deviation from Hardy-Weinberg equilibrium, the Person's χ2-test (1 d.f) was applied. Association analysis of rs17775456 and rs7990537 with obesity measurements was performed using BMI and body weight as continuous traits. The adult men were categorized as overweight (BMI≥25 kg/m2) or normal-weight (BMI<25 kg/m2) before the analysis. Skewed variables were log-transformed and analyzed with linear regression, assuming an additive model. Covariates such as height, age and sex were tested for dependence on the response variables and included in the model if significant. In order to correct for multiple comparisons Bonferroni correction was applied and a p-value≤0.006 was considered statistically significant. All the analyses were performed using PLINK (http://pngu.mgh.harvard.edu/purcell/plin​k/) [42].

Power analysis.

Power calculation was carried out with the CaTS power calculator (www.sph.umich.edu/csg/abecasis/CaTS/inde​x.html) [43] and Power and Sample Size Calculation (biostat.mc.vanderbilt.edu/wiki/Main/Pow​erSampleSize)[44]. For rs17775456 we had 80% power to detect association with overweight and obesity, with a relative risk of 1.2. For rs7990537 we had 80% power to detect association with overweight and obesity with a relative risk of 1.4.

Supporting Information

Figure S1.

ARC neurons of Nbea+/− mice are sensitive to leptin. A: An intraperitoneal injection of leptin at the dose that reduces food intake causes an increase in the density of Fos immunoreactive (IR) nuclei in the ARC of WT and Nbea+/− mice (established bilaterally per mm2 of the tissue on every fourth ARC section). One animal per genotype was injected with saline or leptin (treatment details as in the feeding experiment). An hour later the mice were perfused transcardially with 4% paraformaldehyde. Coronal brain sections (50 µm) were cut on a vibratome and immunostained. Images provided by the camera attached to the Nikon microscope were analyzed using the NIH 1.51 Image software (NIH, MD). Full description of Fos staining in [32]. B: Photomicrographs depicting c-Fos staining in the ARC of saline- (left) versus leptin-treated (right) Nbea+/− mice. VMH, ventromedial hypothalamic nucleus; 3v, 3rd ventricle.

doi:10.1371/journal.pgen.1002568.s001

(TIF)

Acknowledgments

We thank Katarzyna J. Radomska, Uppsala University, for technical help with qPCR. The excellent technical assistance of Reinhard Seeliger, Sabrina Bothur, Michaela Grandl, Elfi Holupirek, Regina Kneuttinger, Ann-Elisabeth Schwarz, Anna Dewert, Brigitte Herrmann, Florian Schleicher, and Susanne Wittich, as well as the animal caretaker team at the GMC, is gratefully acknowledged. We also thank the members of the GMC for comprehensive phenotyping of the Nbea+/− mice and fruitful discussions.

Author Contributions

Conceived and designed the experiments: MWK PKO ASL CM UR JR WW TK EW MK VG-D HF MHdA. Performed the experiments: JAJ SS AK JA PKO JR RE NE BR WH LB SMH. Analyzed the data: JAJ RF JR RE MK BR WH LB SMH MWK. Wrote the paper: PKO HBS JR MK MWK.

References

  1. 1. De Lozanne A (2003) The role of BEACH proteins in Dictyostelium. Traffic 4: 6–12.
  2. 2. Kypri E, Schmauch C, Maniak M, De Lozanne A (2007) The BEACH protein LvsB is localized on lysosomes and postlysosomes and limits their fusion with early endosomes. Traffic 8: 774–783.
  3. 3. de Souza N, Vallier LG, Fares H, Greenwald I (2007) SEL-2, the C. elegans neurobeachin/LRBA homolog, is a negative regulator of lin-12/Notch activity and affects endosomal traffic in polarized epithelial cells. Development 134: 691–702.
  4. 4. Lim A, Kraut R (2009) The Drosophila BEACH family protein, blue cheese, links lysosomal axon transport with motor neuron degeneration. J Neurosci 29: 951–963.
  5. 5. Albers CA, Cvejic A, Favier R, Bouwmans EE, Alessi MC, et al. (2011) Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet 43: 735–740.
  6. 6. Wang X, Herberg FW, Laue MM, Wüllner C, Hu B, et al. (2000) Neurobeachin: A protein kinase A-anchoring, beige/Chediak-higashi protein homolog implicated in neuronal membrane traffic. J Neurosci 20: 8551–65.
  7. 7. Pawson T, Scott JD (1997) Signaling through scaffold, anchoring, and adaptor proteins. Science 278: 2075–80.
  8. 8. Su Y, Balice-Gordon RJ, Hess DM, Landsman DS, Minarcik J, et al. (2004) Neurobeachin is essential for neuromuscular synaptic transmission. J Neurosci 24: 3627–36.
  9. 9. Medrihan L, Rohlmann A, Fairless R, Andrae J, Döring M, et al. (2009) Neurobeachin, a protein implicated in membrane protein traffic and autism, is required for the formation and functioning of central synapses. J Physiol 587: 5095–5106.
  10. 10. Castermans D, Wilquet V, Parthoens E, Huysmans C, Steyaert J, et al. (2003) The neurobeachin gene is disrupted by a translocation in a patient with idiopathic autism. J Med Genet 40: 352–356.
  11. 11. Savelyeva L, Sagulenko E, Schmitt JG, Schwab M (2006) Low-frequency common fragile sites: Link to neuropsychiatric disorders? Cancer Lett 232: 58–69.
  12. 12. O'Neal J, Gao F, Hassan A, Monahan R, Barrios S, et al. (2009) Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma. Exp Hematol 37: 234–244.
  13. 13. Savelyeva L, Sagulenko E, Schmitt JG, Schwab M (2006) The neurobeachin gene spans the common fragile site FRA13A. Hum Genet 118: 551–558.
  14. 14. Gailus-Durner V, Fuchs H, Becker L, Bolle I, Brielmeier M, et al. (2005) Introducing the German Mouse Clinic: open access platform for standardized phenotyping. Nat Methods 2: 403–404.
  15. 15. Gailus-Durner V, Fuchs H, Adler T, Aguilar Pimentel A, Becker L, et al. (2009) Systemic first-line phenotyping. Methods Mol Biol 530: 463–509.
  16. 16. Wagener A, Schmitt AO, Aksu S, Schlote W, Neuschl C, et al. (2006) Genetic, sex, and diet effects on body weight and obesity in the Berlin Fat Mouse Inbred lines. Physiol Genomics 27: 264–270.
  17. 17. Beckers S, Zegers D, Van Gaal LF, Van Hul W (2009) The role of the leptin-melanocortin signalling pathway in the control of food intake. Crit Rev Eukaryot Gene Expr 19: 267–287.
  18. 18. Olszewski PK, Schiöth HB, Levine AS (2008) Ghrelin in the CNS: from hunger to a rewarding and memorable meal? Brain Res Rev 58: 160–170.
  19. 19. Levine AS, Jewett DC, Cleary JP, Kotz CM, Billington CJ (2004) Our journey with neuropeptide Y: effects on ingestive behaviors and energy expenditure. Peptides 25: 505–510.
  20. 20. Grill HJ (2010) Leptin and the systems neuroscience of meal size control. Front Neuroendocrinol 31: 61–78.
  21. 21. Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, et al. (2007) The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 318: 1469–1472.
  22. 22. Kaiyala KJ, Morton GJ, Leroux BG, Ogimoto K, Wisse B, et al. (2010) Identification of Body Fat Mass as a Major Determinant of Metabolic Rate in Mice. Diabetes 59: 1657–1666.
  23. 23. Speakman JR (2010) FTO effect on energy demand versus food intake. Nature 464: E1; discussion E2.
  24. 24. Papadouka V, Carr KD (1994) The role of multiple opioid receptors in the maintenance of stimulation-induced feeding. Brain Res 639: 42–48.
  25. 25. Hayward MD, Schaich-Borg A, Pintar JE, Low MJ (2006) Differential involvement of endogenous opioids in sucrose consumption and food reinforcement. Pharmacol Biochem Behav 85: 601–611.
  26. 26. Yamamoto T, Sako N, Maeda S (2000) Effects of taste stimulation on beta-endorphin levels in rat cerebrospinal fluid and plasma. Physiol Behav 69: 345–350.
  27. 27. Olszewski PK, Grace MK, Fard SS, Le Grevès M, Klockars A, et al. (2010) Central nociceptin/orphanin FQ system elevates food consumption by both increasing energy intake and reducing aversive responsiveness. Am J Physiol Regul Integr Comp Physiol 299: R655–663.
  28. 28. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, et al. (2010) Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42: 937–948.
  29. 29. Niesmann K, Breuer D, Brockhaus J, Born G, Wolff I, et al. (2011) Dendritic spine formation and synaptic function require neurobeachin. Nat Commun 2: 557. (DOI:10.1038/ncomms1565).
  30. 30. O'Rahilly S, Farooqi IS (2008) Human obesity: a heritable neurobehavioral disorder that is highly sensitive to environmental conditions. Diabetes 57: 2905–2910.
  31. 31. Wang JW, Gamsby JJ, Highfill SL, Mora LB, Bloom GC, et al. (2004) Deregulated expression of LRBA facilitates cancer cell growth. Oncogene 23: 4089–4097.
  32. 32. Olszewski PK, Klockars A, Olszewska AM, Fredriksson R, Schiöth HB, et al. (2010) Molecular, immunohistochemical, and pharmacological evidence of oxytocin's role as inhibitor of carbohydrate but not fat intake. Endocrinology 151: 4736–4744.
  33. 33. Lindblom J, Haitina T, Fredriksson R, Schiöth HB (2005) Differential regulation of nuclear receptors, neuropeptides and peptide hormones in the hypothalamus and pituitary of food restricted rats. Brain Res Mol Brain Res 133: 37–46.
  34. 34. Lindblom J, Johansson A, Holmgren A, Grandin E, Nedergård C, et al. (2006) Increased mRNA levels of tyrosine hydroxylase and dopamine transporter in the VTA of male rats after chronic food restriction. Eur J Neurosci 23: 180–186.
  35. 35. Ramakers C, Ruijter JM, Deprez RH, Moorman AF (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339: 62–66.
  36. 36. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: research0034.
  37. 37. Hedstrand H (1975) A study of middle-aged men with particular reference to risk factors for cardiovascular disease. Ups J Med Sci Suppl 191–61.
  38. 38. Jacobsson JA, Risérus U, Axelsson T, Lannfelt L, Schiöth HB, et al. (2009) The common FTO variant rs9939609 is not associated with BMI in a longitudinal study on a cohort of Swedish men born 1920–1924. BMC Med Genet 10: 131.
  39. 39. Jacobsson JA, Danielsson P, Svensson V, Klovins J, Gyllensten U, et al. (2008) Major gender difference in association of FTO gene variant among severely obese children with obesity and obesity related phenotypes. Biochem Biophys Res Commun 368: 476–482.
  40. 40. Rolland-Cachera MF, Sempé M, Guilloud-Bataille M, Patois E, Péquignot-Guggenbuhl F, et al. (1982) Adiposity indices in children. Am J Clin Nutr 36: 178–184.
  41. 41. Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, et al. (2003) Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 68: 69–78.
  42. 42. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
  43. 43. Skol AD, Scott LJ, Abecasis GR, Boehnke M (2006) Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38: 209–213.
  44. 44. Dupont WD, Plummer WD Jr (1998) Power and sample size calculations for studies involving linear regression. Control Clin Trials 19: 589–601.